|
|||||
|
|
Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells |
|
| Authors: | Iain R Hutcheson Janice M Knowlden Steve E Hiscox Denise Barrow Julia MW Gee John F Robertson Ian O Ellis Robert I Nicholson |
| Affiliation: | (1) Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, CF10 3XF Cardiff, UK;(2) Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, NG5 1PB Nottingham, UK |
| Abstract: | IntroductionResistance to anti-epidermal growth factor receptor (anti-EGFR) therapies is an emerging clinical problem. The efficacy of anti-EGFR therapies can be influenced by the presence of heregulins (HRGs), which can bind erbB3/4 receptors and can activate alternative signalling pathways. In the present study we have examined whether HRG signalling can circumvent EGFR blockade in an EGFR-positive tamoxifen-resistant MCF-7 (Tam-R) breast cancer cell line. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |